Patents by Inventor Powel H. Brown

Powel H. Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of an RXR agonist and taxanes in treating Her2+ cancers
    Patent number: 11896558
    Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: February 13, 2024
    Assignees: Io Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS
    Publication number: 20230172890
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Application
    Filed: December 7, 2022
    Publication date: June 8, 2023
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • USE OF AN RXR AGONIST AND TAXANES IN TREATING HER2+ CANCERS
    Publication number: 20230172872
    Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered.
    Type: Application
    Filed: December 7, 2022
    Publication date: June 8, 2023
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS
    Publication number: 20220211652
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Application
    Filed: December 30, 2021
    Publication date: July 7, 2022
    Inventors: Martin E. Sanders, Powel H. Brown
  • Use of an RXR agonist in treating HER2+ cancers
    Patent number: 11224583
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 18, 2022
    Assignee: Io Therapeutics, Inc.
    Inventors: Martin E. Sanders, Powel H. Brown
  • USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS
    Publication number: 20210137871
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Application
    Filed: December 18, 2020
    Publication date: May 13, 2021
    Inventors: Martin E. Sanders, Powel H. Brown
  • Use of an RXR agonist in treating HER2+ cancers
    Patent number: 10966950
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: April 6, 2021
    Assignees: Io Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Martin E. Sanders, Powel H. Brown
  • USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS
    Publication number: 20200390736
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 17, 2020
    Inventors: Martin E. Sanders, Powel H. Brown, M.D., Ph.D.
  • Dominant negative deletion mutants of C-jun and their use in the prevention and treatment of cancer
    Patent number: 6699842
    Abstract: The inhibition of AP-1 activity by dominant negative deletion mutants of c-jun is disclosed. This inhibition of AP-1 activity is shown to be associated with inhibition of tumor promoter-induced neoplastic transformation. Therefore, the invention relates to the utilization of dominant negative deletion mutants of c-jun which are inhibitory to tumor promotor-induced neoplastic transformation as therapeutic agents in the prevention and treatment of cancer in mammals.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: March 2, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nancy H. Colburn, Zigang Dong, Powel H. Brown, Michael J. Birrer